$1.96
(11.02%)
Add to watchlist
Create an alert
Stocks and Shares ISALENZ Therapeutics, Inc. is a pre-commercial stage biopharmaceutical company. The Company is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.
Company Information
About this company
Key people
Evert Schimmelpennink
President, Chief Executive Officer, Secretary, Director
Daniel R. Chevallard
Chief Financial Officer
Marc Odrich
Chief Medical Officer
Shawn Olsson
Chief Commercial Officer
Jeff W. George
Independent Chairman of the Board
Kimberlee Cobleigh Drapkin
Independent Director
Frederic Guerard
Independent Director
James Mccollum
Independent Director
Zachary Scheiner
Independent Director
Click to see more
Key facts
- Shares in issue31.29m
- EPICLENZ
- ISINUS52635N1037
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$583.56m
- Employees42
- ExchangeNASDAQ
- IndexTR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.